TREMFYA® offers a generally well-
tolerated 5-year safety profile,3 with
an MoA that helps avoid important
side effects and IBD,4,5 so clearskin1,3,6-9
comes with peace of mind.

Over 50% of TREMFYA® patients achieved and maintained PASI 100 over 5 years3




MoA-Mode of Action; AE = Adverse event; MACE=Major adverse cardiovascular event; NMSC = Non-melanoma skin cancer; SAE = Serious adverse event; Deaths = completed suicide, epiglottic cancer, liver failure, and astrocytoma
 
TREMFYA® patients reported no new safety signals at 5 years.1

 
 
 
 
 
 
REFERENCES SEE MORE OF THE LATEST DATA
ON THE JANSSEN MEDICAL CLOUD™		 PRESCRIBING
INFORMATION

 
TREMFYA® is indicated for adults with moderate-to-severe plaque
psoriasis (Pso) who are candidates for systemic therapy.10

Tremfya®, alone or in combination with methotrexate (MTX), is indicated
for the treatment of active psoriatic arthritis in adult patients who have
had an inadequate response or who have been intolerant to a prior
disease-modifying antirheumatic drug (DMARD) therapy. 10

Please ensure you review your local Prescribing Information and/or
Summary of Product Characteristics and directly consult
your local Janssen affiliate to address questions.		 Privacy notice  Legal notice

This is published by Janssen Pharmaceutica NV which is solely responsible
for its content. It is intended for EMEA Healthcare professionals.
Third party trademarks used herein are trademarks of their respective owners.
Date of preparation: March 2021.  CP-214600